EDAP TMS

EDAP

Market cap $131M

, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026.

EDAP TMS S.A. (EDAP) Q4 2025 Earnings Call Transcript

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures 69% Full-Year YoY Growth in Focal One System Placements 28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure Growth Demand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today financial results for the fourth quarter and full-year 2025. “We experienced strong global demand for Focal One Robotic HIFU as demonstrated by our 2025 results,” said Ryan Rhodes, Chief Executive Officer.

EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Company to Present and Host 1x1 Investor Meetings on Wednesday, March 18 th , 2026 AUSTIN, Texas, March 10, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Date: Wednesday, March 18th Time: 12:00-12:30 PM ET Format: Virtual Presentation and 1x1 investor meetings Webcast:https://event.summitcast.com/view/2MZVg3DCx8a3zxe3mMMekq/6YGp8gAgsNuJhACXjn75JB The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here.

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before market open on Wednesday, March 25, 2026.

EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) (“the Company” or “EDAP”), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026.

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance 36% to 38% Annual YoY HIFU Revenue Growth, Record Performance  Driven by Increased Focal One ® System Sales and Growth in Number of U.S. Focal One Procedures 69% Annual YoY Growth in Focal One System Placements 28% Q4 YoY Growth in U.S. Procedures Highlights Accelerating Quarterly Procedure Growth AUSTIN, Texas, January 12, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced select preliminary unaudited financial and operational results highlighting record fourth quarter and full-year 2025 HIFU revenue, driven by strong system placements and accelerating procedure growth. The Company also issued initial worldwide revenue guidance for 2026.

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU  AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for new ultrasound imaging and workflow enhancements to the Focal One High Intensity Focused Ultrasound (HIFU) system, further strengthening the company's market leadership in robotic focal therapy for prostate cancer. The 510(k) clearance introduces advanced ultrasound imaging, streamlined treatment planning, and an optimized user-interface to the Focal One i launched earlier this year.

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Tuesday, December 2 nd , 2025 AUSTIN, Texas, November 18, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Chief Executive Officer Ryan Rhodes is scheduled to present and, together with Chief Financial Officer Ken Mobeck, will host 1x1 investor meetings at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City. Date:                     Tuesday, December 2nd Time:                  10:30-10:55 am ET (fireside discussion) Format:                Fireside discussion and 1x1 investor meetings Location:               The Lotte New York Palace  Webcast:              https://event.webcasts.com/starthere.jsp?ei=1743759&tp_key=aa01607b94 The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website here.

EDAP TMS S.A. ( EDAP ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Ryan Rhodes - CEO & Director Ken Mobeck - Chief Financial Officer Conference Call Participants John Fraunces - Lifesci Advisors, LLC Charles Wallace - H.C.